XTalks

MAY 4, 2023

Celiac disease is an autoimmune disorder that is triggered by the consumption of gluten, a protein found in barley, wheat and rye. However, there are ongoing clinical trials for celiac disease to investigate potential new treatments. How does Beyond Celiac spread awareness about research and clinical trials for celiac disease?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Immune Response 98

XTalks

DECEMBER 17, 2021

Xtalks is taking a look at some of the major stories and innovations of the year in the life sciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the life sciences. Life Science Innovations: Malaria and Influenza Vaccines.

Life Science 98

Life Science Vaccination Vaccine Trials 98

XTalks

MARCH 11, 2025

Vepdegestrant, an investigational oral therapy, utilizes PROteolysis TArgeting Chimera (PROTAC) technology a mechanism that harnesses the bodys natural protein disposal system to selectively target and degrade the estrogen receptor.

Trials 59

Trials Clinical Trials Clinical Trials Protein 59

XTalks

JANUARY 7, 2025

Rishi Kundi, a clinical investigator at the University of Maryland Medical System, believes Symvess holds the potential to transform vascular trauma care by overcoming longstanding challenges like infection control and graft failure that have plagued traditional repair methods.

FDA Approval 105

FDA Approval Engineer Clinical Trials Clinical Trials 105

XTalks

OCTOBER 24, 2024

While research is still ongoing, studies suggest that low-calorie diets, the Mediterranean diet and protein restriction may reduce inflammation. Trends in Psoriasis Research: Biologics, Biosimilars and New Therapies Recent innovations in biologics and biosimilars have transformed psoriasis care.

Research 105

Research Dermatology Clinical Trials Clinical Trials 105

XTalks

DECEMBER 26, 2024

Menarini Group has announced positive topline data from the Phase III BROADWAY and TANDEM clinical trials, evaluating obicetrapib and the fixed-dose combination of obicetrapib with ezetimibe. Meanwhile, the TANDEM trial evaluated a fixed-dose combination of obicetrapib with 10 mg ezetimibe in a similar patient population.

Trials 52

Trials Life Science Clinical Trials Clinical Trials 52

XTalks

JULY 19, 2022

The two-dose protein-based, adjuvanted vaccine has been authorized for use in adults 18 years of age and older for the prevention of COVID-19 caused by SARS-CoV-2. In a press release outlining the authorization, the FDA noted that the clinical trial for Novavax’s vaccine was conducted before the appearance of the omicron and delta variants.

Vaccine 94

Vaccine Vaccination Protein Clinical Trials 94

XTalks

DECEMBER 10, 2024

Rilzabrutinib works by targeting BTK, a protein involved in immune cell communication. By inhibiting this protein, the drug disrupts pathways that contribute to platelet destruction and insufficient production. Its selective mechanism aims to minimize off-target effects, making it a potential first-in-class treatment for ITP.

Trials 104

Trials Protein Clinical Development Drugs 104

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccine Vaccination 75

Pharmaceutical Technology

OCTOBER 20, 2022

The funding round saw participation from current investors of the company, Advent Life Sciences and Belinda Termeer. The company will utilise the Series A funds to progress its small molecule drug presently in development into first-in-human clinical trials for advanced metastatic breast cancer.

Development 130

Development Drugs Protein Life Science 130

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 1.351 variant.

Protein 97

Protein Vaccine Vaccination Trials 97

XTalks

APRIL 22, 2022

Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. What is Flow Cytometry? What is a Receptor Occupancy Assay?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

XTalks

NOVEMBER 7, 2022

Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials. Exosome-Based Liquid Biopsy in Oncology.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

JANUARY 21, 2025

By combining a monoclonal antibody against TROP2 a protein frequently overexpressed in cancers with a potent chemotherapy payload, it minimizes damage to healthy cells while attacking tumors effectively. The approval was based on the TROPION-Breast01 trial, which enrolled 732 patients with advanced disease.

Antibody 105

Antibody FDA Approval HR Trials 105

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. SL-172154 entered clinical trials in mid-2020, following promising preclinical results.

Protein 94

Protein Development Clinical Trials Clinical Trials 94

XTalks

MARCH 18, 2025

Incytes recent announcement on the topline results from two Phase III clinical trials of povorcitinib in patients with hidradenitis suppurativa has stirred both hope and caution in the market. By inhibiting this protein, povorcitinib reduces the inflammatory signals that contribute to abscess and nodule formation.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

XTalks

JULY 20, 2022

It is also the first protein-based COVID-19 vaccine to be authorized in the country. Read the full articles here: Novavax Vaccine Becomes First FDA-Authorized Protein Vaccine for COVID-19. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Vaccine Vaccination Drugs 52

XTalks

DECEMBER 29, 2023

Tarlatamab is an investigational drug currently undergoing clinical trials to assess its efficacy in patients with two distinct types of neuroendocrine cancer: SCLC and neuroendocrine prostate cancer (NEPC). Reese, executive vice president of Research and Development at Amgen, in the company’s press release.

Clinical Trials 119

Clinical Trials Clinical Trials FDA Approval Trials 119

XTalks

MAY 10, 2023

Read more about the vaccine, including clinical trial results on its efficacy and safety. The treatment, an antisense oligonucleotide developed by Biogen, targets abnormal proteins arising from SOD1 mutations, which are associated with the development of ALS in some patients.

Life Science 40

Life Science Vaccine Vaccination FDA Approval 40

XTalks

MAY 24, 2022

The FDA has allowed clinical trials assessing the injectable lenacapavir, an investigational long-acting HIV-1 capsid inhibitor in development by Gilead Inc., Lenacapavir is designed to act as an inhibitor of the HIV capsid protein, and it inhibits the virus at distinct stages (early and late) of its life cycle.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

XTalks

MARCH 10, 2025

Live and On-Demand: Wednesday, April 16, 2025, at 1pm EDT (10am PDT) Register for this free webinar to gain insights into how prioritizing patient needs not only boosts enrollment and retention but also revolutionizes the clinical trial landscape.

Medicine 59

Medicine Trials Pharmacy Clinical Trials 59

XTalks

AUGUST 30, 2022

The hemophilia A gene therapy Roctavian delivers a functional gene to enable the body to make an essential blood clotting protein on its own. A lack of sufficient functioning factor VIII and factor IX blood clotting proteins would result in the development of hemophilia A and hemophilia B, respectively.

Gene Therapy 98

Gene Therapy Gene Clinical Trials Clinical Trials 98

XTalks

OCTOBER 23, 2024

Otsuka Pharmaceutical has announced positive interim results from its Phase III clinical trial for sibeprenlimab. The primary endpoint of the trial was a reduction in 24-hour urine protein-to-creatinine ratio (uPCR) compared to placebo after nine months of treatment, which indicates improved kidney function.

Trials 101

Trials Clinical Trials Clinical Trials Antibody 101

Pharmaceutical Technology

MARCH 1, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck KG, is a science and technology company. The company serves healthcare, performance materials, and life sciences markets.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck KG, is a science and technology company. The company serves healthcare, performance materials, and life sciences markets.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

pharmaphorum

JULY 20, 2021

The EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started a 35,000-patient phase 3 trial in May. The post EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine appeared first on.

Vaccine 98

Vaccine Vaccination Protein Immune Response 98

pharmaphorum

JANUARY 11, 2023

Today’s pharmaceutical drug discovery process essentially relies on trial and error,” he expanded. “To To find potential drug candidates, disease-associated protein targets are tested against a small pool of less than ten million distinct chemotypes synthesised at great effort and expense over the past 100 years.

Big Data 122

Big Data Drugs Clinical Trials Clinical Trials 122

XTalks

SEPTEMBER 19, 2024

Mobasher Xtalks Clinical Edge is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials. The mechanism of action of our BTK CDAC allows for complete degradation of the BTK protein and has distinct advantages over current BTK inhibitors.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

XTalks

FEBRUARY 7, 2025

The companys pipeline includes MET-097i, currently in Phase IIb trials, and MET-233i, in early-stage clinical trials. The companys approach combines small molecule therapies and targeted protein degradation. Maze Therapeutics, Inc. IPO Date: January 31, 2025 Initial IPO Price: $16.00

Marketing 66

Marketing Genetics Vaccination Vaccine 66

XTalks

AUGUST 17, 2020

As DMD is caused by a lack of functional dystrophin protein, which supports and strengthens muscle fibers, therapies designed to treat this rare genetic disorder have focused on exon skipping to avoid the area of the dystrophin gene that is mutated and produce a nearly full-length dystrophin protein.

Drugs 105

Drugs Clinical Trials Clinical Trials Gene 105

XTalks

JANUARY 26, 2023

The US Food and Drug Administration (FDA) recently granted approval for the Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) based on the results from two Phase III clinical trials. Brukinsa is now approved to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

FDA Approval 97

FDA Approval Life Science Clinical Trials Clinical Trials 97

XTalks

JULY 17, 2023

protein on the surface of gastric epithelial cells, which display abnormal expression levels of this protein compared to normal cells. Phase III Clinical Trials Underpinning the Applications The applications are grounded on two Phase III clinical trials, SPOTLIGHT and GLOW. How Does Zolbetuximab Work?

Clinical Trials 95

Clinical Trials Clinical Trials Trials Antibody 95

XTalks

DECEMBER 12, 2023

The world of neuroscience trials is rapidly evolving, presenting new challenges and opportunities for researchers and clinicians. The worldwide market for neurology clinical trials stood at a valuation of $5.24 There is currently a heightened emphasis on imaging and liquid biomarkers in neuroscience clinical trials.

Trials 111

Trials Clinical Trials Clinical Trials Genetics 111

XTalks

AUGUST 8, 2022

Medicxi is a prominent international life sciences investment firm that invested in over 60 portfolio companies such as Versanis Bio, Rivus Pharmaceuticals, Capella Bioscience and more. One of Medicxi’s portfolio companies called MiroBio is set to be acquired by Gilead Sciences for approximately $405 million in cash.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

XTalks

JANUARY 3, 2024

In individuals affected by ATTR, which includes both hereditary and wild-type (non-hereditary) variants, the TTR protein forms fibrils that accumulate in various tissues. Safety and Efficacy of Wainua The FDA’s approval of Wainua is underpinned by compelling clinical data. This conjugation facilitates ASO delivery to hepatocytes.

FDA Approval 105

FDA Approval Protein RNA Clinical Trials 105

XTalks

FEBRUARY 19, 2025

It occurs when a genetic error causes the overproduction of a protein called CSF1, which attracts inflammatory cells to the joint, often causing pain, swelling and reduced mobility. Looking ahead, Deciphera is exploring additional clinical trials and potential collaborations in the TGCT space.

FDA Approval 59

FDA Approval Drugs Trials Clinical Trials 59

pharmaphorum

JULY 18, 2022

Convidencia’s injectable version was granted World Health Organization (WHO) Emergency Use Listing (EUL), and its inhalant counterpart, currently in phase three clinical trials, has shown enormous promise. “It is programmed and coded for the production of the full-length spike protein of the coronavirus.

Vaccine 138

Vaccine Vaccination Development Immune Response 138